ARTICLE | Financial News
Immunoproteasome company Kezar files for $80.5M IPO
May 25, 2018 9:08 PM UTC
Kezar Life Sciences Inc. (South San Francisco, Calif.) filed Thursday to raise $80.5 million in an IPO on NASDAQ underwritten by Jefferies, Cowen, Wells Fargo and William Blair.
Kezar is developing immunoproteasome-targeted therapeutics to selectively suppress the hyperactive immune cells that drive autoimmunity. It was spun out from the Onyx Pharmaceuticals Inc. subsidiary of Amgen Inc. (NASDAQ:AMGN) in 2015 (see BioCentury, Sept 22, 2017)...